Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 10/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27189181 | 0.88 | ALDH1A1 (0.42) | ALDH1A1KDM4ETSHRTDP1CA1 | |
| SCHEMBL27306404 | 0.83 | ALDH1A1 (0.42) | ALDH1A1KDM4ETSHRTDP1CA1 | |
| SCHEMBL4655024 | 0.83 | ALDH1A1 (0.42) | ALDH1A1KDM4ETSHRTDP1CA1 | |
| SCHEMBL9787541 | 0.82 | ERN1 (0.48) | CA1CA2ERN1TRIM24TYR | |
| SCHEMBL27581741 | 0.80 | ALDH1A1 (0.39) | ALDH1A1KDM4ETSHRTDP1CA1 | |
| SCHEMBL5759448 | 0.80 | PRKDC (0.44) | ALDH1A1KDM4ETSHRTDP1CA1 | |
| SCHEMBL17263379 | 0.80 | ALDH1A1 (0.53) | ALDH1A1KDM4ETSHRTDP1ERN1 | |
| SCHEMBL448336 | 0.79 | ALDH1A1 (0.39) | ALDH1A1KDM4ETDP1CA1CA2 | |
| SCHEMBL31166894 | 0.79 | ALDH1A1 (0.42) | ALDH1A1KDM4ETSHRTDP1CA1 | |
| SCHEMBL27547025 | 0.79 | TUBB1 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339871-A1 | COMPOUNDS AND METHODS OF MODULATING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 | METREA BIOSCIENCES INC (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4200286-A1 | COMPOUNDS AND METHODS OF MODULATING 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 | Metrea Biosciences, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| CN-115916762-A | Compounds and methods for modulating 17 beta-hydroxysteroid dehydrogenase type 13 | 梅特雷亚生物科学股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| WO-2022040324-A1 | COMPOUNDS AND METHODS OF MODULATING 17β-ΗYDROXYSTEROID DEHYDROGENASE TYPE 13 | METREA BIOSCIENCES, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | disclosed |
| CN-106255679-B | As NAThe heterocyclic compound and application thereof of V channel inhibitor | 默克专利有限公司 | 2019-09-06 | — | — | CN | disclosed |
| CN-109516982-A | Mu-opioid receptor agonist, preparation method thereof and application thereof in medicine field | 上海华汇拓医药科技有限公司 | 2019-03-26 | — | — | CN | disclosed |
| CN-109134451-A | 1,3- 2-substituted carbamide class and thiourea derivatives and its application | 遵义医学院 | 2019-01-04 | — | — | CN | disclosed |
| US-9884839-B2 | Inhibitors of 17Beta-hydroxysteroid dehydrogenases type 1 and type 2 | ELEXOPHARM GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| CN-106255679-A | As Naheterocyclic compound of V channel inhibitor and application thereof | 默克专利有限公司 | 2016-12-21 | — | — | CN | disclosed |
| US-20030040545-A1 | (R)-Chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2003-02-27 | — | — | US | disclosed |
| CN-1398264-A | Indol-3-yl derivatives | MERCK PATENT GMBH (DE) | 2003-02-19 | — | — | CN | disclosed |
| US-6521607-B1 | Preventing coronary artery disease | PHARMACIA CORPORATION | 2003-02-18 | — | — | US | disclosed |
| US-20020177708-A1 | (R)-chiral halogenated substituted N-benzyl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-28 | — | — | US | disclosed |
| EP-1115695-A1 | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(N+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | disclosed |
| CN-1299365-A | Hygromycin A derivatives | PFIZER PROD INC (US) | 2001-06-13 | — | — | CN | disclosed |
| CN-1056373-C | Process for preparing fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | PFIZER (US) | 2000-09-13 | — | — | CN | disclosed |
| WO-2000018724-A1 | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
| CN-1220658-A | Calcium Receptor Active Compounds | NPS PHARMA INC (US) | 1999-06-23 | — | — | CN | disclosed |
| CN-1067655-A | FLUOROALKOXYBENZYLAMINO DERIVATIVES OF NITROGEN CONTAINING HETEROCYCLES | PFIZER (US) | 1993-01-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | TPH1, KYNU, TPH2 | ALDH1A1 606/4885KDM4E 2770/4885TSHR 343/4885 |
| US-20020177708-A1 | (R)-chiral halogenated substituted N-benzyl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | ALDH1A1 2708/4885KDM4E 3846/4885TSHR 2273/4885 |
| US-20030040545-A1 | (R)-Chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, PLTP | ALDH1A1 3571/4885KDM4E 3708/4885TSHR 1592/4885 |
| US-20230339871-A1 | COMPOUNDS AND METHODS OF MODULATING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 | HSD17B1, HSD17B13, HSD17B11 | ALDH1A1 114/4885KDM4E 3023/4885TSHR 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.